Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy

Radiotherapy and Oncology

Volumn 117, Issue 3, 2015, Pages 509-514

  Andrzejewski, Piotr ^a   Kuess, Peter ^a   Knäusl, Barbara ^a   Pinker, Katja ^a,b   Georg, Petra ^a,c   Knoth, Johannes ^a   Berger, Daniel ^a   Kirisits, Christian ^a   Goldner, Gregor ^a   Helbich, Thomas ^a,b   Pötter, Richard ^a   Georg, Dietmar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Dept of Biomedical Imaging and Image guided Therapy ^*  (Austria)

^c EBG MedAustron GmbH   (Austria)

Author keywords

DIL; HDR BT; IMPT; Prostate cancer; SIB; VMAT

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TARGET VOLUME; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOMINANT INTRAPROSTATIC LESION; DOSIMETRY; FEASIBILITY STUDY; HIGH DOSE RATE BRACHYTHERAPY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED PROTON THERAPY; INTERMEDIATE RISK PATIENT; MALE; MULTILEAF COLLIMATOR; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ORGANS AT RISK; PLANNING TARGET VOLUME; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOTHERAPY PLANNING SYSTEM; TUMOR VOLUME; VOLUMETRIC MODULATED ARC THERAPY; ADULT; AGED; BLADDER; INTENSITY MODULATED RADIATION THERAPY; PHOTON; PROCEDURES; PROSTATIC NEOPLASMS; PROTON THERAPY; RADIATION RESPONSE; RECTUM; THERAPEUTIC USE;

ADULT; AGED; BRACHYTHERAPY; FEASIBILITY STUDIES; HUMANS; MALE; ORGANS AT RISK; PHOTONS; PROSTATIC NEOPLASMS; PROTON THERAPY; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; URINARY BLADDER;

EID: 84940881353     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.07.028     Document Type: Article

References (44)

1. [1] Kupelian, P.A., Potters, L., Khuntia, D., et al. Radical prostatectomy, external beam radiotherapy <72Gy, external beam radiotherapy > or = 72Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004), 25–33.
2. [2] Goldner, G., Pötter, R., Battermann, J.J., et al. Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients. Radiother Oncol 103 (2012), 223–227.
3. [3] Grimm, P., Billiet, I., Bostwick, D., et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109 (2012), 22–29.
4. [4] Mayr, N.A., Hawighorst, H., Yuh, W.T., Essig, M., Magnotta, V.A., Knopp, M.V., MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome. J Magn Reson Imaging 10 (1999), 267–276.
5. [5] Barentsz, J.O., Richenberg, J., Clements, R., et al. ESUR prostate MR guidelines 2012. Eur Radiol 22 (2012), 746–757.
6. [6] Al-Mamgani, A., Heemsbergen, W.D., Levendag, P.C., et al. Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiother Oncol 96 (2010), 13–18.
7. [7] Zietman, A.L., Bae, K., Slater, J.D., et al. Randomized trial comparing conventional-dose with high dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95–09. J Clin Oncol 28 (2010), 1106–1111.
8. [8] Pollack, A., Zagars, G.K., Starkschall, G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002), 1097–1105.
9. [9] Dearnaley, D.P., Sydes, M.R., Graham, J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007), 475–487.
10. [10] Cellini, N., Morganti, A.G., Mattiucci, G.C., et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53 (2002), 595–599.
11. [11] Pucar, D., Hricak, H., Shukla-Dave, A., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 69 (2007), 62–69.
12. [12] Pinkawa, M., Piroth, M.D., Holy, R., et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer – evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol, 7, 2012, 14.
13. [13] van Lin, E.N., Futterer, J.J., Heijmink, S.W., et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 65 (2006), 291–303.
14. [14] Ippolito, E., Mantini, G., Morganti, A.G., et al. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Am J Clin Oncol 35 (2012), 158–162.
15. [15] Miralbell, R., Molla, M., Rouzaud, M., et al. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys 78 (2010), 50–57.
16. [16] Gaudet, M., Vigneault, E., Aubin, S., et al. Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: a prospective comparative toxicity analysis. Int J Radiat Oncol Biol Phys 77 (2010), 153–159.
17. [17] Fonteyne, V., Villeirs, G., Speleers, B., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 72 (2008), 799–807.
18. [18] De Meerleer, G., Villeirs, G., Bral, S., et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 75 (2005), 325–333.
19. [19] Singh, A.K., Guion, P., Sears-Crouse, N., et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study. Radiat Oncol, 2, 2007, 36.
20. [20] Bauman, G., Haider, M., Van der Heide, U.A., Ménard, C., Boosting imaging defined dominant prostatic tumors: a systematic review. Radiother Oncol 107 (2013), 274–281.
21. [21] Steiner, E., Georg, D., Goldner, G., Stock, M., Prostate and patient intrafraction motion: impact on treatment time-dependent planning margins for patients with endorectal balloon. Int J Radiat Oncol Biol Phys 86 (2013), 755–761.
22. [22] Góra, J., Stock, M., Lütgendorf-Caucig, C., Georg, D., Is there an advantage in designing adapted, patient-specific PTV margins in intensity modulated proton beam therapy for prostate cancer?. Int J Radiat Oncol Biol Phys 85 (2013), 881–888.
23. [23] Lips, I.M., van der Heide, U.A., Haustermans, K., et al. Single blind randomized Phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials, 12, 2011, 255.
24. [24] Christodouleas, J.P., Tang, S., Susil, R., The effect of anterior proton beams in the setting of a prostate-rectum spacer. Med Dosim 38 (2013), 315–319.
25. [25] Soukup, M., Fippel, M., Alber, M., A pencil beam algorithm for intensity modulated proton therapy derived from Monte Carlo simulations. Phys Med Biol 50 (2005), 5089–5104.
26. [26] Hillbrand, M., Georg, D., Assessing a set of optimal user interface parameters for intensity-modulated proton therapy planning. J Appl Clin Med Phys, 11, 2010, 3219.
27. [27] Hoskin, P., Rojas, A., Ostler, P., et al. High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity. Radiother Oncol 110 (2014), 268–271.
28. [28] ICRP. ICRP statement on tissue reactions/early and late effects of radiation in normal tissues and organs – threshold doses for tissue reactions in a radiation protection context. ICRP Publication 118. Ann. ICRP 2012; 41(1/2).
29. [29] Deasy, J.O., Blanco, A.I., Clark, V.H., CERR: a computational environment for radiotherapy research. Med Phys 30 (2003), 979–985.
30. [30] Niemierko, A., A generalized concept of equivalent uniform dose (EUD). Med Phys, 26, 1999, 1100.
31. [31] Gay, H.A., Niemierko, A., A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Phys Med 23 (2007), 115–125.
32. [32] Fatyga, M., Williamson, J.F., Dogan, N., et al. A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study. Med Phys 36 (2009), 3995–4006.
33. [33] ICRU, ICRU report 83/prescribing, recording, and reporting intensity-modulated photon-beam therapy (IMRT). J ICRU, 1, 2010.
34. [34] Georg, D., Hopfgartner, J., Góra, J., et al. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 88 (2014), 715–722.
35. [35] Kirisits, C., Rivard, M., Baltas, D., et al. Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM. Radiother Oncol 110 (2014), 199–212.
36. [36] Smeenk, R.J., Hoffmann, A.L., Hopman, W.P., van Lin, E.N., Kaanders, J.H., Dose–effect relationships for individual pelvic floor muscles and anorectal complaints after prostate radiotherapy. Int J Radiat Oncol Biol Phys 83 (2012), 636–644.
37. [37] Roach, M. 3rd, Nam, J., Gagliardi, G., El Naqa, I., Deasy, J.O., Marks, L.B., Radiation dose–volume effects and the penile bulb. Int J Radiat Oncol Biol Phys 76 (2010), 130–134.
38. [38] McNeal, J.E., Redwine, E.A., Freiha, F.S., Stamey, T.A., Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 (1988), 897–906.
39. [39] Vogelius, I.R., Bentsen, S.M., Meta analysis of alpha/beta ratio for prostate cancer in the presence of an overall time factor. Bad news, good news or no news?. Int J Radiat Oncol Biol Phys 85 (2013), 89–94.
40. [40] Emami, B., Lyman, J., Brown, A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991), 109–122.
41. [41] Burman, C., Kutcher, G.J., Emami, B., Goitein, M., Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 21 (1991), 123–135.
42. [42] Brenner, D.J., Fractionation and late rectal toxicity. Int J Radiat Oncology Biol Phys 60 (2004), 1013–1015.
43. [43] Michalski, J.M., Gay, H., Jackson, A., et al. Radiation dose–volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 76 (2010), 123–129.
44. [44] Gloi, A.M., Buchanan, R., Dosimetric assessment of prostate cancer patients through principal component analysis (PCA). J Appl Clin Med Phys, 14, 2013, 3882.